Mycobacterium tuberculosis, the causative agent of tuberculosis, remains the leading cause of infectious disease worldwide, affecting approximately a quarter of the globe's population. Treatment of infections is problematic ...
Biochemistry
Jul 21, 2022
0
83
An FDA-approved drug for hepatitis C can increase bacterial sensitivity to antibiotics and reduce the likelihood of antibiotic resistance, according to a new study led by New York University researchers published in Cell ...
Biochemistry
Nov 23, 2021
0
97
For a slow-growing microbe that multiplies infrequently, Mycobacterium tuberculosis, the pathogen that causes tuberculosis (TB) has long puzzled researchers as to how it develops resistance to antibiotics so quickly, in a ...
Evolution
Nov 18, 2020
0
45
Crick and Imperial researchers have found that a key antibiotic widely used to treat drug-resistant tuberculosis does not work as expected—a finding which could be used to develop new drugs. The study was part-funded by ...
Cell & Microbiology
Mar 16, 2020
0
24
A team of physicists from Immanuel Kant Baltic State University have suggested a method to identify single antibiotic-resistant tuberculosis-causing bacteria. The new method detects the bacteria and evaluates their resistance ...
Biochemistry
Feb 13, 2019
0
5
A Brock University research team has created a microscopic robot that has the potential to identify drug resistance to tuberculosis faster than conventional tests.
Biochemistry
Jul 24, 2018
0
35
Combining the innovations of synthetic biology with biology and chemistry, a team of scientists at the University of Bristol have generated a brand-new platform that will allow the production of desperately needed brand-new ...
Biochemistry
Nov 28, 2017
0
45
A novel way of synthesising a promising new antibiotic has been identified by scientists at the University of Bristol. By expressing the genes involved in the production of pleuromutilin in a different type of fungus, the ...
Biochemistry
May 4, 2016
1
303
A chemist based at the University of Copenhagen has just taken out a patent for a drug that can make previously multidrug-resistant bacteria once again responsive to antibiotics. Jørn Bolstad and his chemist colleagues hope ...
Biochemistry
Feb 17, 2014
0
0
To stay ahead in the race against drug-resistant infections, scientists constantly search for and exploit vulnerabilities in deadly bacteria. Now, researchers from Brown and the Massachusetts Institute of Technology have ...
Biochemistry
Sep 18, 2013
1
0
Active tuberculosis will kill about two of every three people affected if left untreated. Treated tuberculosis has a mortality rate of less than 5%.
The standard "short" course treatment for tuberculosis (TB), is isoniazid, rifampicin, pyrazinamide, and ethambutol for two months, then isoniazid and rifampicin alone for a further four months. The patient is considered cured at six months (although there is still a relapse rate of 2 to 3%). For latent tuberculosis, the standard treatment is six to nine months of isoniazid alone.
If the organism is known to be fully sensitive, then treatment is with isoniazid, rifampicin, and pyrazinamide for two months, followed by isoniazid and rifampicin for four months. Ethambutol need not be used.
This text uses material from Wikipedia, licensed under CC BY-SA
